Biogen and AbbVie said today they are voluntarily withdrawing Zinbryta® (daclizumab) from the market worldwide. The withdrawal came as the European Medicines Agency started an “urgent review” of the relapsing multiple sclerosis (MS) treatment under its Article 20 referral procedure following seven cases of serious inflammatory brain disorders in Germany—including encephalitis and meningoencephalitis—and one case in Spain. The companies also told …

Biogen May Be The Only Legitimate Hope For Bringing An Alzheimer’s Drug To Market Summary Biogen has set the state to potentially bring an FDA approved treatment out to early stage patients with Alzheimer’s. An interim analysis of a phase 1b study and a long-term study shows that increased doses reduce the amount of amyloid plaque in patients with Alzheimer’s. …

Biogen will develop and commercialize Alkermes’ Phase III multiple sclerosis (MS) treatment ALKS 8700, the companies said today, through an up-to-$228 million-plus collaboration designed to neutralize a potential competitive challenge to Biogen’s MS blockbuster Tecfidera® (dimethyl fumarate). ALKS 8700 is an oral, novel, and proprietary monomethyl fumarate (MMF) prodrug candidate in development for the treatment of relapsing forms of MS. …

Summary Bioverativ is a rare blood disease company. It has two products on the market. It generates enough free cash flow to finance the development of its pipeline. Biogen Spin-off Spin-offs have a history of outperformance. Alcoa (NYSE: AA) is a good example. Another example is Bioverativ (NASDAQ: BIVV), the hemophilia-business unit that was spun off from Biogen (NASDAQ:BIIB) earlier this year. In 2007, Biogen …